Ochre Health

ochrehealth.com.au

Ochre Health is an Australian medical services organisation with over 33 Medical Centres that specialises in providing healthcare services in urban, regional and remote communities throughout NSW, QLD, VIC, TAS and the ACT. Since 2002, our goal has been to improve healthcare outcomes within our communities by providing exceptional doctors (GP, VMO and Procedural), supported by highly trained practice support staff and operational management. Our sites range from remote (RA4) locations, such as Boggabri, Condobolin and Queenstown, where hospital on-call services are also provided by our doctors, to District of Workforce Shortage (DWS) locations in Canberra and on the Sunshine Coast in Queensland.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

National Medtech & Biotech Summit 2024

Conference

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

Related News

NOVARTIS COLLABORATES WITH DNDI FOR VISCERAL LEISHMANIASIS DRUG

Pharmaceutical Technology | February 25, 2020

Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis. LXE408 is an oral treatment for this parasitic disease, which is transmitted by the bite of a sand fly, and can be life-threatening if left untreated. The drug was initially discovered by Novartis with the financial backing of the Wellcome Trust. DNDi executive direct...

AMAG PHARMACEUTICALS ANNOUNCES CHANGES TO MEDICAL DEVELOPMENT ORGANIZATION

Send Press Releases with GlobeNewswire | March 04, 2020

AMAG Pharmaceuticals, Inc. today announced changes to its medical development organization. Effective March 31, 2020, Julie Krop, M.D., Executive Vice President and Chief Medical Officer, will be leaving the Company. As AMAG initiates a search for a permanent Chief Medical Officer, the Board of Directors and management will continue to work closely with the medical development organization on key priorities, including working with the U.S. Food and Drug Administration (FDA) to find a path to ret...

CORRECTING AND REPLACING CIRCLE PHARMA RAISES $45 MILLION IN SERIES B FINANCING

Business Wire | March 17, 2020

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $45 million in a Series B financing. The financing was led by The Column Group, with participation by Nextech Invest. All investors from the prior round – ShangPharma, LifeForce Capital, and the Berkeley Catalyst Fund – joined the financing. In conjunction with the financing, Peter Svennilson, founder and managing partner of The Column Gro...

PHARMACY MARKET

IAMBIC THERAPEUTICS ANNOUNCES CLOSE OF OVERSUBSCRIBED $100 MILLION SERIES B FINANCING TO ADVANCE AI-DISCOVERED THERAPEUTICS INTO CLINICAL DEVELOPMENT

Business Wire | October 10, 2023

Iambic Therapeutics a biotechnology company developing novel therapeutics from its unique generative AI discovery platform, today announced the closing of an oversubscribed $100 million Series B financing co-led by Ascenta Capital and Abingworth, and also including new investors NVIDIA, Illumina Ventures, Gradiant Corporation, and independent board member Bill Rastetter. Existing inve...